Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Phase 2TerminatedNCT00202540

Institut de Recherches Internationales Servier38 enrolled

Overview

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Mild Cognitive Impairment

Interventions

S18986DRUG

Eligibility

Sex: ALLMin age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Memory complaint * Acetylcholinesterase inhibitors stopped at least 3 months before selection Exclusion Criteria: * Dementia * Parkinson's disease * Vascular disorder * Depression * Epilepsy

Locations (1)

Hôpital la Grave-Casselardit

Toulouse, France

Outcomes

Primary Outcomes

Episodic memory

Secondary Outcomes

Other cognitive domains, activities of daily living, global impression of change, MRI, safety.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.